Document:

Exhibit 10.7

 

ASSET PURCHASE AGREEMENT

 

This Asset Purchase
Agreement (this  “Agreement”) is made and entered into effective as of January 5, 2015 (the  “Effective
Date”), by and between Arog Pharmaceuticals, Inc., a Delaware corporation ( “Seller”), and Videra Pharmaceuticals,
LLC a Delaware limited liability company ( “Buyer”). Seller and Buyer are sometimes referred to herein as the
 “Parties,” and each, a  “Party.”

 

RECITALS

 

WHEREAS, Seller desires
to contribute, transfer, assign, convey, set over, grant sell and deliver (collectively,  “Transfer”) to Buyer
the assets identified on Exhibit A attached hereto (the  “Purchased Assets”) free and clear of all Liens
other than Permitted Liens; and

 

WHEREAS, the aggregate
consideration for the Purchased Assets shall be One Hundred Twenty Five Thousand Dollars ($125,000) (the  “Purchase Price”)
and Buyer’s assumption of certain liabilities of Seller identified on Exhibit B attached hereto (the  “Assumed
Liabilities”).

 

NOW, THEREFORE, in
consideration of the mutual agreements set forth herein, and subject to the terms and provisions set forth below, the Parties hereto
agree as follows:

 

AGREEMENT

 

1. Defined Terms.
For purposes of this Agreement, the terms defined in this Section 1 shall have the meanings herein specified unless the context
otherwise requires.

 

1.1  “Contract”
means any written or oral legally binding contract, agreement, instrument, commitment or undertaking of any nature.

 

1.2
 “Excluded Assets” means any assets of Seller that are not Purchased Assets.

 

1.3  “Governmental Entity” means any: (a) nation, state, county, city, district or other similar jurisdiction of
any nature; (b) federal, state, local or foreign government; (c) governmental or quasi-governmental authority of any nature (including
any governmental agency, branch, commission, bureau, instrumentality, department, official, entity, court or tribunal); (d) multinational
organization or body; or (e) body or other Person entitled by applicable Law, contract or other arrangement to exercise any arbitrative,
administrative, certification, executive, judicial, legislative, licensing, police, regulatory or taxing authority or power.

 

1.4  
 “Law” means any applicable provision of any constitution, treaty, statute, law (including the common law), rule,
regulation, ordinance, code or order enacted, adopted, issued or promulgated by any Governmental Entity.

 

1.5  
 “Liability” means any liability or obligation of any kind or nature (whether known or unknown, asserted or unasserted,
absolute or contingent, accrued or unaccrued, liquidated or unliquidated, or due or to become due).

 

     

     

    

1.6  
 “Lien” means any mortgage, claim, pledge, security interest, charge, lien, option or other right to purchase,
restriction or reservation or any other encumbrance whatsoever.

 

1.7 
 “Material Adverse Effect” means, with respect to any Person, any incident, condition, change, effect or circumstance
that, individually or when taken together with all such incidents, conditions, changes, effects or circumstances in the aggregate,
has had or would reasonably be expected to have a material adverse effect on the business, operations, condition (financial or
otherwise), properties, Liabilities, results of operations or prospects of such Person and its subsidiaries, taken as a whole or
any of them taken individually.

 

1.8 
 “Permitted Lien” means any: (a) Lien for any tax, assessment or other governmental charge that is not yet due
and payable or that may thereafter be paid without penalty; or (b) mechanic’s, materialmen’s, landlord’s or similar
Lien arising or incurred in the ordinary course of business of the applicable Person that secures any amount that is not overdue;
or (c) any license to intellectual property rights.

 

1.9 
 “Person” means any individual, partnership, corporation, limited liability company, association, joint stock
company, trust, joint venture, unincorporated organization or any other business entity or association or any Governmental Entity.

 

2.   Transfer
of Assets; Assumption of Liabilities: Issuance of Shares. The closing (the  “Closing”) of the transactions
contemplated by this Agreement (the  “Asset Sale”) shall be consummated effective as of 12:01 a.m. Central
Time on the Effective Date. At the Closing, (i) Seller shall Transfer the Purchased Assets to Buyer, free and clear of all Liens
other than Permitted Liens, and (ii) Buyer shall assume the Assumed Liabilities and pay to Seller the Purchase Price via wire
transfer of immediately available funds to an account designated by Seller. In connection with the Asset Sale, at the Closing,
Seller and Buyer shall enter into (A) an Assignment and Assumption Agreement and Bill of Sale substantially in the form attached
hereto as Exhibit C, (B) a Patent Assignment substantially in the form attached hereto as Exhibit D  and (B) a License Agreement
substantially in the form attached hereto as Exhibit E. The Parties acknowledge that no consideration, other than as specifically
recited herein, is or will be received by Seller in exchange for the Transfer of the Purchased Assets set forth herein. Notwithstanding
any other provision of this Agreement, Buyer shall not assume any Liabilities of Seller nor any affiliate of Seller other than
the Assumed Liabilities.

 

3.
Representations and Warranties.

 

3.1 
Representations and Warranties of Seller. Seller represents and warrants to Buyer as of the Effective Date as follows:

 

(a)  
Organization and Standing. Seller is a corporation duly organized and validly existing under the Laws of the State of Delaware.
Seller has the requisite corporate power and authority to own the Purchased Assets and to conduct its business as now being conducted,
and is duly qualified to do business and is in good standing in each jurisdiction in which the ownership or leasing of its properties
or assets or the conduct of its business requires such qualification, except where the failure to be so qualified or in good standing
has not had and would not reasonably be expected to have a Material Adverse Effect on Seller.

 

 

    2 

     

    

(b)  
Authority . Seller has the requisite company power and authority to execute and deliver and perform its obligations under
this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of” this Agreement and
the consummation of the transactions contemplated hereby have been duly authorized by all necessary corporate action on the part
of Seller. This Agreement has been duly executed and delivered by Seller and constitutes the legal, valid and binding obligations
of Seller, enforceable against Seller in accordance with its terms, except to the extent that enforceability may be limited by
the effect, if any, of any applicable bankruptcy, reorganization, insolvency, moratorium or other Laws affecting the enforcement
of creditors’ rights generally or any general principles of equity, regardless of whether such enforceability is considered
in a proceeding at law or in equity. Neither the execution and delivery by Seller of this Agreement nor the consummation of the
transactions contemplated hereby will conflict with or violate any provision of Seller’ s Certificate of Incorporation or
Bylaws, each as amended to date.

 

(c)  
Governmental Approvals. No consent, approval, order or authorization of, or registration, qualification, designation, declaration
or filing with any Governmental Entity, is required on the part of Seller in connection with the Transfer of the Purchased Assets
to Seller and the other transactions contemplated by this Agreement and the other documents contemplated hereby.

 

3.2 
Representations and Warranties of Buyer. Buyer represents and warrants to Seller as of the Effective Date as follows:

 

(a)  
Organization and Standing. Buyer is a limited liability company duly organized and validly existing under the Laws of the
State of Delaware. Buyer has the requisite company power and authority to own its assets and properties and to carry on its business
as now being conducted and is duly qualified to do business and is in good standing in each jurisdiction in which the ownership
or leasing of its properties or assets or the conduct of its business requires such qualification, except where the failure to
be so qualified or in good standing has not had and would not reasonably be expected to have a Material Adverse Effect on Buyer.

 

(b)  
Authority. Buyer has the requisite company power and authority to execute and deliver and perform its obligations under
this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement and the consummation
of the transactions contemplated hereby have been duly authorized by all necessary corporate action on the part of Buyer. This
Agreement has been duly executed and delivered by Buyer and constitutes the legal, valid and binding obligations of Buyer, enforceable
against Buyer in accordance with its terms, except to the extent that enforceability may be limited by the effect, if any, of any
applicable bankruptcy, reorganization, insolvency, moratorium or other Laws affecting the enforcement of creditors’ rights
generally or any general principles of equity, regardless of whether such enforceability is considered in a proceeding at law or
in equity. Neither the execution and delivery by Buyer of this Agreement nor the consummation of the transactions contemplated
hereby will conflict with or violate any provision of Buyer’s Certificate of Formation or Limited Liability Company Agreement,
each as amended to date.

 

 

    3 

     

    

(c)  Governmental Approvals.
No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any Governmental
Entity is required on the part of Buyer in connection with the receipt of the Purchased Assets, assumption of the Assumed Liabilities
and the other transactions contemplated by this Agreement and the other documents contemplated hereby.

 

3.3 The representations
and warranties of Seller and the Buyer contained in Section 3 of this Agreement shall expire and be of no further force
or effect as of the date that is twelve (12) months after the date of the Closing.

 

4. Notices. All
notices and other communications hereunder shall be in writing and shall be deemed received (a) on the date of delivery if delivered
personally or by messenger service, (b) on the date of confirmation of receipt of transmission by facsimile (or, the first business
day following such receipt if (i) the date is not a business day or (ii) confirmation of receipt is given after 5:00 p.m., Pacific
Time) or (c) on the date of confirmation of receipt if delivered by a nationally recognized courier service (or, the first business
day following such receipt if (i) the date is not a business day or (ii) confirmation of receipt is given after 5:00 p.m., Pacific
Time), to the Parties at the following address or facsimile numbers (or at such other address or facsimile number for a Party as
shall be specified by like notice):

 

if to Seller, to:

 

Arog Pharmaceuticals, Inc.

Two Lincoln Centre 

5420 LBJ Freeway, Suite 410

Dallas, Texas 75240 

Fax: (469) 533-3966

Attention: CEO

 

if to Buyer, to:

 

Videra Pharmaceuticals, LLC 

Two Lincoln Centre

5420 LBJ Freeway, Suite 410 

Dallas, Texas 75240

Fax: (214) 889-7070 

Attention: CEO

 

5.  
Amendment. The Parties may cause this Agreement to be amended at any time by execution of an instrument in writing signed
on behalf of each of the Parties, except as otherwise required by Law.

 

6.  
Further Assurances. Each Party hereto shall, from time to time after the Closing, at the request of any other Party hereto
in writing and without further consideration, execute and deliver such other instruments of conveyance, assignment, transfer and
assumption, and take such other actions, as such other Party may reasonably request to more effectively consummate the transactions
contemplated by this Agreement.

 

 

    4 

     

    

7.  
Wrong Pocket. In the event that after the Closing, Seller or any of its affiliates receives any payment related to any Purchased
Asset, Seller agrees to use commercially reasonable efforts to remit any such payment within five (5) business days (or cause to
be remitted within five (5) business days) such funds to Buyer, but in any event such funds shall be remitted to Buyer as soon
as possible thereafter. In the event that Buyer or any of its affiliates receives any payment related to any Excluded Assets after
the Closing, Buyer agrees to use commercially reasonable efforts to remit any such payment within five (5) business days (or cause
to be remitted within five (5) business days) such funds to Seller, but in any event such funds shall be remitted to Seller as
soon as possible thereafter.

 

8.   Assignment:
Successors and Assigns. None of the rights and obligations of Seller or Buyer may be assigned without the prior written consent
of Buyer or Seller, respectively, and any purported assignment made without such consent shall be void; provided, however,
that the rights and obligations of a Party may be assigned and delegated without the other Party’s consent (a)  in
connection with a transfer, merger, acquisition, reorganization or consolidation of such Party, or with a sale of all or substantially
all of such Party’ s assets, (b) to any affiliate of such Party, or (c) to any successor Person who purchases the business
of such Party. Subject to the foregoing, this Agreement (and the rights and obligations hereunder) shall be binding upon and shall
inure to the benefit of the Parties hereto and their respective successors and permitted assigns (each of which successors and
permitted assigns shall be deemed to be a Party hereto for all purposes of this Agreement).

 

9.  
Waiver. Any Party may, to the extent legally allowed, (a) extend the time for the performance of any of the obligations
or other acts of the other Party, (b) waive any inaccuracies in the representations and warranties made to such Party contained
herein or in any document delivered pursuant hereto and (c) waive compliance with any of the agreements or conditions for the benefit
of such Party contained herein. Any such extension or waiver by any Party shall not operate or be construed as a further or continuing
extension or waiver. Any agreement on the part of a Party to any such extension or waiver shall be valid only if set forth in an
instrument in writing signed on behalf of such Party.

 

10.    
Severability. In the event that any provision of this Agreement, or the application thereof, becomes or is declared by a
court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force
and effect and the application of such provision to other Persons or circumstances will be interpreted so as reasonably to effect
the intent of the Parties.

 

11.    
Governing Law. This Agreement and all disputes and controversies arising hereunder shall be governed by and construed in
accordance with the Laws of the State of Delaware without reference to such state’s principles of conflicts of law.

 

12.    
Waiver of Jury Trial. EACH PARTY WAIVES ANY RIGHT TO TRIAL BY JURY IN ANY DISPUTE, WHETHER SOUNDING IN CONTRACT, TORT, OR
OTHERWISE, AMONG THE PARTIES ARISING OUT OF OR RELATED TO THE TRANSACTIONS CONTEMPLATED HEREBY. ANY PARTY MAY FILE AN ORIGINAL
COUNTERPART OR A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF

 

 

    5 

     

    

THE CONSENT OF THE PARTIES TO THE WAIVER OF THEIR RIGHT TO TRIAL
BY JURY.

 

13.    
Attorneys’ Fees. Should any party institute any proceeding in court or otherwise to enforce any provision hereof or
for damages by reason of alleged breach of any provision of this Agreement, the prevailing party shall be entitled to receive from
the non-prevailing party such reasonable out-of-pocket expenses (including attorneys’ fees and expenses) incurred by the
prevailing party in connection with any such proceeding.

 

14.    
Counterpart Execution. This Agreement may be executed in one or more counterparts, all of which shall be considered one
and the same agreement and shall become effective when one or more counterparts have been signed by each of the Parties and delivered
to the other Party, it being understood that all Parties need not sign the same counterpart. The Parties may sign this Agreement
in the original, by facsimile, by .PDF or by any other generally acceptable electronic means.

 

15.    
Interpretation; Construction. In this Agreement: (a) the section headings are for convenience of reference only and will
not affect the meaning or interpretation of this Agreement; (b) the words  “herein,”  “hereunder,”
 “hereby” and similar words refer to this Agreement as a whole (and not to the particular sentence, paragraph
or section where they appear); (c) terms used in the plural include the singular, and vice versa, unless the context clearly requires
otherwise; (d) unless expressly stated herein to the contrary, reference to any document means such document as amended or modified
and as in effect from time to time in accordance with the terms thereof; (e) unless expressly stated herein to the contrary, reference
to any applicable Law means such applicable Law as amended, modified, codified, replaced or reenacted, in whole or in part, and
as in effect from time to time, including any rule or regulation promulgated thereunder; (f) the words  “including,”
 “include” and variations thereof are deemed to be followed by the words  “ without limitation;”
(g)  “or” is used in the sense of  “and/or;”  “any” is used in the sense of
 “any or all;” and  “with respect to” any item includes the concept  “of’ such
item or  “under” such item or any similar relationship regarding such item; (h) unless expressly stated herein
to the contrary, reference to a document, including this Agreement, will be deemed to also refer to each annex, addendum, exhibit,
schedule or other attachment thereto; (i) unless expressly stated herein to the contrary, reference to a section, schedule or
exhibit is to a section, schedule or exhibit, respectively, of this Agreement; (j) when calculating a period of time, the day
that is the initial reference day in calculating such period will be excluded and, if the last day of such period is not a business
day, such period will end on the next day that is a business day; (k)  with respect to all dates and time periods in or referred
to in this Agreement, time is of the essence; and (l) the phrase  “the date hereof ‘ means the date of this Agreement,
as stated in the first paragraph hereof.

 

[Remainder of page intentionally Left blank]

 

 

    6 

     

    

IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be executed as of the date first set forth above.

 

 

	 	AROG PHARMACEUTICALS, INC.

                     

                     

	 	By:	/s/ Vinay Jain
	 	 	Name:	Vinay Jain, M.D.
	 	 	Title:	CEO

 

 

	 	VIDERA PHARMACEUTICALS, LLC

                     

                     

	 	By:	/s/ Vinay Jain
	 	 	Name:	Vinay Jain, M.D.
	 	 	Title:	Manager

 

     

     

    

EXHIBIT A

 

Purchased Assets

 

		1.	All of Seller’ s rights under the Contracts set forth on Schedule 1 hereto (collectively,
the  “Transferred Contracts”), including all claims, contract rights and warranty and product liability claims
against third parties under the Transferred Contracts.

 

		2.	All Intellectual Property set forth on Schedule 2 and all rights of copyright in the tangible
embodiments of the items identified below in Paragraphs 3 and 4 that are primarily related to the Purchased Assets
(collectively, the  “Transferred IP”), and all rights to sue for or assert claims against and remedies against
past, present or future infringement s or misappropriation of any or all of the Transferred IP, and rights of priority and protection
of interests therein and to retain any and all amounts therefrom.

 

		3.	All data, records, files, manuals, blueprints and other documentation primarily related to the
Purchased Assets, including: (i) service and warranty records; (ii) studies, reports, correspondence and other similar documents
and records primarily related to the Purchased Assets, whether in electronic form or otherwise; and (iv) copies of all accounting
and tax books, ledgers and records and other financial records primarily related to the Purchased Assets.

 

		4.	All policies and procedures, methods of delivery of services, disks, drawings and specifications,
market studies, consultants’ reports and prototypes, primarily related to the Purchased Assets.

 

     

     

    

EXHIBIT B

 

Assumed Liabilities

 

		1.	All Liabilities arising with respect to Buyer’ s use or exploitation of the Purchased Assets
following the Closing, including all Liabilities arising under the Transferred Contracts following the Closing.

 

     

     

    

EXHIBIT C

 

Assignment and Assumption Agreement and Bill of Sale

 

     

     

    

ASSIGNMENT AND ASSUMPTION AGREEMENT AND BILL OF
SALE

 

This Assignment and
Assumption Agreement and Bill of Sale (this  “Agreement”) is made and entered into as of January 5, 2015, by
and between Arog Pharmaceuticals, Inc., a Delaware corporation ( “Assignor”), and Videra Pharmaceuticals, LLC,
a Delaware limited liability company ( “Assignee”).

 

RECITALS

 

A. Assignor and Assignee
are parties to that certain Asset Purchase Agreement dated as the date of this Agreement (the  “Purchase Agreement”),
pursuant to which Assignor has agreed to contribute, transfer, assign, convey, set over, grant, sell and deliver ( “Transfer”)
to Assignee the Purchased Assets and Assignee has agreed to assume the Assumed Liabilities.

 

AGREEMENT

 

NOW, THEREFORE, for
and in consideration of the promises and the mutual covenants contained herein, and for other good and valuable consideration,
the receipt, adequacy and legal sufficiency of which are hereby acknowledged, the parties do hereby agree as follows:

 

1.  
Capitalized Terms. Capitalized terms used but not defined herein shall have the meanings for such terms that are set forth
in the Purchase Agreement.

 

2.  
Contribution and Transfer of Assets. Pursuant to the terms of the Purchase Agreement, Assignor hereby Transfers to Assignee
and its successors and assigns, effective as of 12:01 a.m. Central Time on the date hereof (the  “Effective Time”),
all of Assignor’s right, title and interest in and to all of the Purchased Assets free and clear of all Liens other than
Permitted Liens and the Assumed Liabilities. Effective as of the Effective Time, Assignee hereby accepts the Transfer of all of
Assignor’s right, title and interest in and to all of the Purchased Assets.

 

3.  
Assumption. Pursuant to the terms of the Purchase Agreement, effective as of the Effective Time, Assignee hereby assumes and
agrees to pay, discharge and perform all of the duties, obligations, terms, provisions and covenants of the Assumed Liabilities.
In no event does Assignee assume or otherwise have any liability for any other liability (or portion thereof) of Assignor and the
parties hereto agree that all other liabilities shall remain the sole responsibility of Assignor.

 

4.  
Third Parties. The assumption by Assignee of the Assumed Liabilities as herein provided is not intended by the parties to expand
the rights or remedies of any third party against Assignee as compared to the rights and remedies which such third party would
have had against Assignor had Assignee not consummated the transactions contemplated by the Purchase Agreement and this Agreement.
Nothing herein contained shall, or shall be construed to, prejudice the right of Assignee to contest any claim or demand by such
a third party with respect to any obligation or liability assumed hereunder, and Assignee shall be entitled to defend or contest
any such claim or demand in any and all respects from and after the date hereof.

 

     

     

    

5. Terms
of the Purchase Agreement. Nothing herein contained shall itself change, amend, extend, enlarge, limit or alter (nor shall
it be deemed or construed as changing, amending, extending, enlarging, limiting or altering) the terms or conditions of the Purchase
Agreement in any manner whatsoever. This instrument does not create or establish liabilities or obligations not otherwise created
or existing under or pursuant to the Purchase Agreement. In the event of any conflict or inconsistency between the terms of the
Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern.

 

6.  
Governing Law. This Agreement and all disputes and controversies arising hereunder shall be governed by and construed in accordance
with the Laws of the State of Delaware without reference to such state’s principles of conflicts of law.

 

7.  
Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their
respective successors and permitted assigns (each of which successors and permitted assigns shall be deemed to be a party hereto
for all purposes of this Agreement).

 

8.  
Severability. In the event that any provision of this Agreement, or the application thereof, becomes or is declared by a court
of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force and
effect and the application of such provision to other Persons or circumstances will be interpreted so as reasonably to effect the
intent of the Parties.

 

9.  
Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same
agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the
other party, it being understood that all parties need not sign the same counterpart. The parties may sign this Agreement
in the original, by facsimile, by .PDF or by any other generally acceptable electronic means.

 

10.   
Transferred Contracts and Permits. Notwithstanding any other provision of this Agreement or the Purchase Agreement, this Agreement
does not constitute an agreement to assign or transfer, or effect an assignment or transfer, of any Transferred Contract or permit
if the parties have not obtained a required consent to assignment or transfer as of the Closing and an attempted assignment or
transfer thereof without the consent of a third party would constitute a breach or other contravention thereof or a violation
of law or would in any way adversely affect the rights of Assignor or Assignee or any of their affiliates thereto or thereunder.
As to any Transferred Contract or permit referred to in the previous sentence, the parties agree to continue to use commercially
reasonable efforts from and after the Closing to obtain any required consent(s).

 

[Remainder of Page Intentionally Left Blank]

 

     

     

    

IN WITNESS WHEREOF,
each of the parties has caused this Agreement to be executed on its behalf by their respective officers thereunto duly authorized
all as of the date first written above.

 

 

	 	

“ASSIGNOR”

 

AROG
PHARMACEUTICALS, INC.

 

                     

	 	By:	/s/ Vinay Jain
	 	 	Name:	Vinay Jain, M.D.
	 	 	Title:	CEO

 

 

	 	

                    “ASSIGNEE”

 

Videra
Pharmaceuticals, LLC

                     

                     

	 	By:	/s/ Vinay Jain
	 	 	Name:	Vinay Jain, M.D.
	 	 	Title:	Manager

 

 

     

     

    

EXHIBIT D

 

Patent Assignment Agreement

 

     

     

    

PATENT ASSIGNMENT

 

This PATENT ASSIGNMENT
(this  “Assignment”) is made and entered into as of January 5, 2015 (the  “Effective Date”)
by and between Arog Pharmaceuticals, Inc., a Delaware corporation ( “Assignor”), and Videra Pharmaceuticals,
LLC, a Delaware limited liability company ( “Assignee”).

 

WHEREAS, pursuant to
that certain Asset Purchase Agreement (the  “Purchase Agreement”), dated January 5, 2015 between Assignor and
Assignee, Assignor has agreed to sell, assign, transfer, convey, and deliver to Assignee all of Assignor’s right, title,
and interest in and to certain assets, including, without limitation, the Assigned Patents (defined below); and

 

WHEREAS, pursuant to
the Purchase Agreement, Assignor and Assignee have agreed to enter into this Assignment.

 

NOW, THEREFORE, in
consideration of the promises and covenants set forth in the Purchase Agreement and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

 

1.  
Conveyance. Assignor hereby sells, assigns, transfers, conveys, and delivers to Assignee and Assignee hereby accepts
all of Assignor’s right, title and interest in, to and under the issued patents and patent applications listed on Schedule
A, including, without limitation (i) all reissues, divisionals, continuations, continuations-in-part, revisions, reexaminations,
extensions, and counterparts (whether foreign or domestic) claiming priority to or based on any of the foregoing items, together
with all patents issuing therefrom, (ii) all inventions and improvements claimed or described in any of the foregoing, including
without limitation all rights of priority under international conventions, treaties, or agreements, (iii) all rights to collect
royalties and proceeds in connection with any of the foregoing (collectively (i)-(iii) above, the  “Assigned Patents”),
(iv) all rights to prosecute and maintain any of the foregoing, and (v) rights to sue and bring other claims for past, present
and future infringement, misappropriation, or other violation of any of the foregoing and all rights to recover and retain damages
(including attorneys’ fees and expenses) or lost profits in connection therewith.

 

2.  
Recordation. Assignor hereby requests the United States Patent and Trademark Office Commissioner for Patents and
any other applicable governmental entity or registrar (including any applicable foreign or international office or registrar),
to record Assignee as the assignee and owner of the Assigned Patents. Assignor also hereby authorizes the respective patent office
or governmental agency in each jurisdiction to issue any and all patents or certificates of invention which may be granted upon
any of the Assigned Patents in the name of Assignee, as the assignee to the entire interest therein.

 

3.  
Information and Assistance.

 

3.1  
Upon Assignee’s reasonable request and without further compensation, Assignor shall execute, acknowledge, and deliver
all the instruments and documents and shall take all the actions reasonably necessary or required by law to consummate and make
fully effective the transaction contemplated by this Assignment.

 

3.2  
If Assignee is unable for any reason to secure Assignor’s signature to any document required to file, prosecute, register,
or memorialize the assignment of any rights under any Assigned Patents as provided under this Assignment, Assignor hereby irrevocably
designates and appoints Assignee and Assignee’s duly authorized officers and agents as Assignor’s agents and attorneys-in-fact
to act for and on Assignor’s behalf and instead of Assignor to take all lawfully permitted acts to further the

 

     

     

    

filing, prosecution, registration, memorialization
of assignment, issuance, and enforcement of rights under such Assigned Patents, all with the same legal force and effect as if
executed by Assignor. The foregoing is deemed a power coupled with an interest and is irrevocable.

 

4.  
Successors and Assigns. This Assignment and all the provisions hereof shall be binding upon and shall inure to the
benefit of the parties hereto and their respective successors and permitted assigns. Nothing herein, express or implied, shall
give or be construed to give to any person, other than the parties hereto and such permitted assigns, any legal or equitable rights
hereunder.

 

5.  
Counterparts. This Assignment may be executed in two or more consecutive counterparts (including by facsimile), each
of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. The
Assignment shall become effective when each party has signed one or more counterparts, and delivered them (by facsimile or otherwise)
to the other party.

 

6.  
Purchase Agreement Controls. This Assignment is provided pursuant to the Purchase Agreement, to which reference is
made for a further statement of the rights and obligations of Assignor and Assignee with respect to the Assigned Patents. Nothing
contained in this Assignment shall be deemed to modify, supersede, enlarge, or affect the rights of any person under the Purchase
Agreement. If any provision of this Assignment is inconsistent or conflicts with the Purchase Agreement, the Purchase Agreement
shall control.

 

7.  
Governing Law. This Assignment and all claims or causes of action (whether in contract, tort or otherwise) that may
be based upon, arise out of or relate to this Assignment or the negotiation, execution, or performance of this Assignment shall
be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice or conflict
of law provision or rule.

 

[Signature Page Follows]

 

     

     

    

IN WITNESS WHEREOF, the undersigned have
caused this Patent Assignment to be executed, effective as of the Effective Date

 

	 	
        ASSIGNOR:

         

        AROG PHARMACEUTICALS, INC.

         

	 	By:	 
	 	Name:	Vinay Jain, M.D.
	 	Title:	Chief Executive Officer
	 	 	 
	 	Address :
	 	 
	 	
        Two Lincoln Centre

        

        5420 LBJ Freeway, Suite 410 

        Dallas, Texas 75240

         

	 	 
	 	Acknowledged and Accepted:
	 	 
	 	
        ASSIGNEE:

         

        VIDERA PHARMACEUTICALS, LLC

         

	 	By:	 
	 	Name:	Vinay Jain, M.D.
	 	Title:	Manager
	 	 
	 	Address:
	 	 
	 	
        Two Lincoln Centre

        

        5420 LBJ Freeway, Suite 410 

        Dallas, Texas 75240

         

 

     

     

    

SCHEDULE A TO PATENT ASSIGNMENT

 

Method of Inhibiting FLT3 Kinase

 

		·	Application Number: 14/447,139

 

		·	Filing Date: July 30, 2014

 

		o	Patent Cooperation Treaty, filed with the United States Patent and Trademark Office (USPTO)

 

		·	First Named Inventor: Vinay K. Jain

 

		·	Internal Reference Number: AROG: 1003

 

     

     

    

EXHIBIT E

 

License Agreement

 

[Filed as Exhibit 10.6 to this Registration
Statement]

 

 

     

     

    

SCHEDULE 1

 

Transferred Contracts

 

		·	New York University School of Medicine - Material Transfer Agreement

 

		o	Effective April 1, 2014

 

		o	Tuberculosis

 

		o	PI: Joel D. Ernst

 

		o	Crenolanib Besylate

 

		·	Genon Biotechnologies, Ltd.

 

		o	Effective July 12, 2013

 

		o	JAK assays for selectivity

 

		o	PI: Olli Silvennoinen

 

		o	CP-637,451

 

     

     

    

SCHEDULE 2

 

Transferred IP

 

Patent Applications

 

		·	AROG:1003

 

		o	Application No. 14/447,139

 

		o	Method of Inhibiting FLT3 Kinase - CP-673451

 

Domain Name(s)

 

		·	Viderapharma.com

 

Know-how primarily related to the Purchased Assets

 

 

     

     

    

SCHEDULE 3

 

Tangible Assets

 

Compounds

 

	Compound Number (non-GMP Materials)	Salt Name	Total Milligrams (Approximate)	Lot#
	CP-673451	Base	1,052,800	041511-124-03
	CP-673451-01	Hydrochloride salt	5,300	047886-274-01
	CP-673451-10	Citrate salt	151	Various Lot Number(s)
	CP-673451-14	Acetate salt	16	Various Lot Number(s)
	CP-673451-15	P-Touluene sulphonate salt	3,700	Various Lot Number(s)
	CP-673451-24	Succinate salt	22	Various Lot Number(s)
	CP-673451-27	 	5	Various Lot Number(s)
	CP-673451-42	 	6	Various Lot Number(s)Exhibit 10.8

 

 

First
Amendment to the January S, 2015, License Agreement between

AROG Pharmaceuticals, Inc. and Videra Pharmaceuticals, LLC

 

This
Amendment (“Amendment”), dated June 22, 2018, (the “Amendment Effective Date”) is made by
and between AROG Pharmaceuticals, Inc., (hereinafter referred to as “Company”), with a place of business at 5420 LBJ
Freeway, Ste. 410, Dallas, Texas 75240, United States, and Videra Pharmaceuticals, LLC (hereinafter referred to as “Licensee”),
with a place of business at 5420 LBJ Freeway, Suite 410, Dallas, TX 75240, United States. Company and Licensee are each individually
referred to herein as a “Party” and collectively as the “Parties.”

 

WHEREAS,
Company and Licensee entered into a License Agreement effective January 5, 2015 (the “Agreement”);

 

WHEREAS,
the Agreement concerns Licensee’s desire to obtain from Company an exclusive license under certain patents, know-how and
other intellectual property owned by or licensed to Company; and

 

WHEREAS,
the Parties wish to amend this Agreement to clarify the intent of the original license granted to Licensee.

 

NOW,
THEREFORE, in consideration of the mutual covenants set forth in this Amendment and in the Agreement, and other good and valuable
consideration which is hereby acknowledged, the Parties agree to amend the Agreement as follows:

 

		1.	Section
                                         2.l(b) Licenses to Licensee, shall be deleted in its entirety and replaced with the following:

 

“a
non-exclusive, royalty-bearing, sublicensable (subject to Section 2.3) license, under the Company Patents and the Company Know-How
, to research, develop , use, sell, offer for sale, import, make, and have made Licensee Products in the Territory (other than
Lead Company Product in the Company Primary Field).”

 

Except as
modified herein, the Agreement, remains in full force and effect and is hereby incorporated by this reference. Capitalized terms
not otherwise defined herein shall have the meanings contained in the Agreement.

 

IN WITNESS
WHEREOF, the Parties have caused this Amendment to be executed by their duly authorized representatives as of the Amendment
Effective Date.

 

	AROG Pharmaceuticals, Inc.	 	Videra Pharmaceuticals, LLC
	 	 	 
	 	 	 
	By:	/s/
    Edward McDonald	 	By:	/s/
    Vinay Jain, M.D.
	 	 	 	 	 

	Name:	Edward McDonald	 	Name:	Vinay Jain, M.D.
	 	 	 	 	 
	Title:	Sr. Corporate Counsel	 	Title:	Manager
	 	 	 	 	 
	Date:	22 - June – 2018	 	Date:	June 22 2018

 

 

AROG.Videra-Amendment
to License Agreement

22 June 2018

Page 1 of l

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]